Prostate-specific antigen screening: Pro

Current Opinion in Urology

Volumn 20, Issue 3, 2010, Pages 185-188

  Loeb, Stacy ^a   Catalona, William J ^b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Detection; Prostate cancer; Prostate specific antigen; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADVANCED CANCER; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; EVIDENCE BASED MEDICINE; HISTOPATHOLOGY; HUMAN; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; REVIEW;

HUMANS; MALE; MASS SCREENING; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 77951298043     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOU.0b013e3283384047     Document Type: Review

References (28)

1. Stamey TA, Yang N, Hay AR, et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987; 317:909-916. (Pubitemid 17147932)
2. Nadler RB, Humphrey PA, Smith DS, et al. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate-specific antigen levels. J Urol 1995; 154 (2 Pt 1):407-413.
3. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995; 273:289-294.
4. Loeb S, Roehl KA, Antenor JA, et al. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology 2006; 67:316-320. (Pubitemid 43189848)
5. Lilja H, Ulmert D, Bjork T, et al. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. J Clin Oncol 2007; 25:431-436. (Pubitemid 350002992)
6. Fang J, Metter EJ, Landis P, et al. Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging. Urology 2001; 58:411-416. (Pubitemid 32816360)
7. Carter HB, Ferrucci L, Kettermann A, et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 2006; 98:1521-1527. (Pubitemid 44680903)
8. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or 4.0 ng per millilitre. N Engl J Med 2004; 350:2239-2246.
9. Antenor JA, Roehl KA, Eggener SE, et al. Preoperative PSA and progressionfree survival after radical prostatectomy for Stage T1c disease. Urology 2005; 66:156-160.
10. Kundu SD, Roehl KA, Yu X, et al. Prostate specific antigen density correlates with features of prostate cancer aggressiveness. J Urol 2007; 177:505-509. (Pubitemid 46054032)
11. Loeb S, Sutherland DE, D'Amico AV, et al. PSA velocity is associated with gleason score in radical prostatectomy specimen: marker for prostate cancer aggressiveness. Urology 2008; 72:1116-1120; discussion 1120.
12. Stephenson AJ, Kattan MW, Eastham JA, et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostatespecific antigen era. J Clin Oncol 2009; 27:4300-4305.
13. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004; 351:125-135.
14. D'Amico AV, Renshaw AA, Sussman B, Chen MH. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 2005; 294:440-447. (Pubitemid 41124176)
15. Partin AW, Yoo J, Carter HB, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993; 150:110-114. (Pubitemid 23175983)
16. Cooperberg MR, Pasta DJ, Elkin EP, et al. The University of California, San Francisco, Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 2005; 173:1938-1942.
17. Kattan MW, Eastham JA, Stapleton AM, et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998; 90:766-771. (Pubitemid 28259189)
18. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360:1320-1328.
19. Van Leeuwen PJ, Connolly D, Gavin A, et al. Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit. Eur J Cancer 2009. [Epub ahead of print]
20. Jemal A, Thun MJ, Ries LA, et al. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 2008; 100:1672-1694.
21. Etzioni R, Gulati R, Falcon S, Penson DF. Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach. Med Decision Making 2008; 28:323-331. (Pubitemid 351713299)
22. Etzioni R, Tsodikov A, Mariotto A, et al. Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control 2008; 19:175-181.
23. Kvale R, Auvinen A, Adami HO, et al. Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries. J Natl Cancer Inst 2007; 99:1881-1887. (Pubitemid 351767195)
24. Bartsch G, Horninger W, Klocker H, et al. Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality. BJU Int 2008; 101:809-816. (Pubitemid 351347736)
25. Roobol MJ, Kerkhof M, Schroder FH, et al. Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). Eur Urol 2009. [Epub ahead of print]
26. Andriole GL, Grubb RL 3rd, Buys SS, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360:1310-1319.
27. Cooperberg MR, Carroll PR. Prostate-cancer screening. N Engl J Med 2009; 361:203; author reply 204-205.
28. Andriole GL, Levin DL, Crawford ED, et al. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial. J Natl Cancer Inst 2005; 97:433-438. (Pubitemid 40528606)